title: Platelet FcgammaRIIA receptor surface expression is increased in patients with ESRD and is associated with atherosclerotic cardiovascular events.
abstract: BACKGROUND
  Accelerated atherogenesis is a prominent feature of end-stage renal disease (ESRD).
  
  
  METHODS
  Expression of platelet FcgammaRIIA immunoglobulin G receptor (FcgammaR) was measured in 2 populations: (1) 48 patients with ESRD with a mean age of 50.7 +/- 2.3 (SEM) years and (2) 48 healthy age- and sex-matched controls aged 53.6 +/- 1.6 years.
  
  
  RESULTS
  Platelet FcgammaR expression was enhanced significantly in patients with ESRD (mean fluorescence intensity [MFI], 7.88 +/- 0.42 [SEM]; 95% confidence interval [CI], 7.03 to 8.72 versus 5.07 +/- 0.21; 95% CI, 4.64 to 5.49; P < 0.0001). In patients with ESRD, multivariate analysis showed that hemoglobin level and diastolic blood pressure were related inversely to FCgammaR expression (P = 0.01 and P = 0.03, respectively). Atherosclerotic cardiovascular events (ACVEs) were recorded prospectively for the ESRD cohort. A total of 22 ACVEs, defined as the occurrence of myocardial infarction (10 events), cerebrovascular accident (7 events), and/or a peripheral vascular event (5 events), were observed. In the group with greater receptor expression (MFI > 7.785; n = 24), 13 of 17 patients (76.5%) experienced at least 1 ACVE, whereas only 4 of 17 patients (23.5%) with low FcgammaR expression (MFI < 7.785; n = 24) experienced an event (P = 0.007).
  
  
  CONCLUSIONS
  (1) Uremia is associated with enhanced platelet FcgammaR expression, and (2) patients with greater platelet FcgammaR expression are significantly more likely to experience ACVEs; however, (3) the small sample size is a limitation and our work therefore is a hypothesis-generating pilot study that remains to be confirmed.
authors.affiliation: Department of Medicine, Division of Nephrology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. elshahaw@usc.edu
authors.forename: Mohamed
authors.initials: M
authors.lastname: El-Shahawy
authors.forename: Mazen
authors.initials: M
authors.lastname: Noureddin
authors.forename: Hesham
authors.initials: H
authors.lastname: Abdullah
authors.forename: Wendy J
authors.initials: WJ
authors.lastname: Mack
authors.forename: David C
authors.initials: DC
authors.lastname: Calverley
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000096:biosynthesis*; D050197:Atherosclerosis / Q000150:complications / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000150:complications / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism*; D008875:Middle Aged; D011446:Prospective Studies; D017452:Receptors, IgG / Q000096:biosynthesis*
chemical_list: D015703:Antigens, CD; C080568:Fc gamma receptor IIA; D017452:Receptors, IgG